Reaction
Peak Expiratory Flow Rate Decreased reporting signals
As of the last recalculation, Peak Expiratory Flow Rate Decreased appears in 436 FAERS reports alongside 15 co-occurring drug terms. The strongest observed disproportionality signal is CICLESONIDE (PRR 129.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ciclesonide | 34 | 129.2 | 129.5 |
| Omalizumab | 109 | 81.1 | 81.2 |
| Timolol | 14 | 57.1 | 57.2 |
| Salmeterol Xinafoate | 10 | 56.7 | 56.7 |
| Liothyronine Sodium | 9 | 50.4 | 50.4 |
| Mepolizumab | 46 | 49.3 | 49.3 |
| Fluticasone Propionate And Salmeterol Xinafoate | 47 | 41.8 | 41.8 |
| Budesonide And Formoterol Fumarate Dihydrate | 65 | 37.4 | 37.4 |
| Tiotropium Bromide | 82 | 35.0 | 35.0 |
| Tiotropium Bromide Inhalation Spray | 8 | 34.7 | 34.7 |
| Loperamide Hydrochloride Oral | 7 | 33.2 | 33.3 |
| Dexlansoprazole | 23 | 27.7 | 27.8 |
| Mometasone Furoate And Formoterol Fumarate Dihydrate | 7 | 21.8 | 21.8 |
| Fluticasone Propionate And Salmeterol | 17 | 20.2 | 20.2 |
| Benralizumab | 8 | 19.4 | 19.4 |